Roche Gains With Tecentriq IMpower131 NSCLC Data, But For How Long?
Executive Summary
Roche is "first to market" with Phase III Tecentriq data in first-line squamous NSCLC setting, but analysts note Merck and Bristol are not far behind.
You may also be interested in...
Merck's Stellar Keytruda Squamous Lung Cancer Data Refute Naysayers
In Phase III KEYNOTE-407 of squamous NSCLC, Keytruda/chemo combo shows overall survival benefit, which was reassuring news for doctors – and investors – ahead of ASCO.
Immuno-Oncology: What To Watch At ASCO 2018
Cancer immunotherapy is once again set to dominate the upcoming American Society of Clinical Oncology annual meeting, with a continuing showdown for PD-1 inhibitors in lung cancer, a CAR-T battle, and disappointments for new IO classes.
Merck Files Keytruda/Chemo Combo Early With FDA In 1L Squamous Lung Cancer
Also, Bristol has filed its Opdivo/Yervoy IO combination in Europe for first-line NSCLC, including squamous and non-squamous disease, based on CheckMate 227 data; some analysts expect FDA will accept the same dataset.